REPURPOSING OF AN APPROVED DRUG SPECIFIC FOR VARIOUS NEUROLOGICAL CONDITIONS

Invex is a biopharmaceutical company focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised intracranial pressure, such as Idiopathic Intracranial Hypertension (IIH), acute stroke and traumatic brain injury. Invex has trade marked its repurposed Exenatide as Presendin™. Following a successful Phase II clinical trial in May 2020, the Company will now progress Presendin™ into a Phase III registration study in IIH.

  ASX ANNOUNCEMENTS

  PRESENTATIONS

Phase II Clinical Results and Capital Raising Presentation – 22 May 2020

  SUBSCRIBE TO UPDATES

  CONTACT INFORMATION

Address
Level 1, 38 Rowland St

Subiaco Perth WA 6008

Phone

+61 (08) 6382 0137

ACN 632145334

Email

info@invextherapeutics.com

Disclaimer. Copyright © Invex Therapeutics. All rights reserved. Site developed by NFIC Services.